Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:2826-2831
doi: 10.1161/hc4801.099737
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herkert, O.
Right arrow Articles by Schini-Kerth, V. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herkert, O.
Right arrow Articles by Schini-Kerth, V. B.
Related Collections
Right arrow Pathophysiology
Right arrow Arterial thrombosis
Right arrow Deep vein thrombosis
Right arrow Thrombin
Right arrow Thrombosis risk factors

(Circulation. 2001;104:2826.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Sex Steroids Used in Hormonal Treatment Increase Vascular Procoagulant Activity by Inducing Thrombin Receptor (PAR-1) Expression

Role of the Glucocorticoid Receptor

Olaf Herkert, PhD; Herbert Kuhl, PhD; Jurgen Sandow, PhD; Rudi Busse, MD, PhD; Valérie B. Schini-Kerth, PhD

From the Institut für Kardiovaskuläre Physiologie (O.H., R.B., V.B.S.-K.), Zentrum der Frauenheilkunde und Geburtshilfe (O.H., H.K.), and Zentrum der Pharmakologie (J.S.), Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany.

Correspondence to V.B. Schini-Kerth, PhD, Pharmacologie et Physicochimie des Interactions Cellulaires et Moléculaires, UMR CNRS 7034, Faculté de Pharmacie, 74, route du Rhin BP 24, F-67401 Illkirch, France. E-mail schini{at}aspirine.u-strasbg.fr

Background— The use of sex steroids in oral contraception or hormonal replacement therapy is associated with an increased risk of cardiovascular thromboembolic complications. Although both the estrogen and the progestin components have been involved, the underlying mechanisms responsible are unclear.

Methods and Results— This study examined whether sex steroids promote hemostasis indirectly by increasing the procoagulant activity of blood vessels. Treatment of vascular smooth muscle cells with several progestins (progesterone, 3-keto-desogestel, gestodene, and medroxyprogesterone acetate) upregulated proteolytically activatable thrombin receptor (PAR-1) expression, resulting in a potentiated thrombin-induced tissue factor expression and surface procoagulant activity. In contrast, neither the progestins levonorgestrel, norethisterone, and norgestimate nor the synthetic estrogen 17{alpha}-ethinylestradiol had such effects. The effect of the stimulatory progestins, which induce glucocorticoid-like effects in several cell systems, was mimicked by dexamethasone and inhibited by the progesterone and glucocorticoid receptor antagonist RU-38486. In addition, long-term administration of progesterone, 3-keto-desogestrel, or medroxyprogesterone acetate to ovariectomized rats increased PAR-1 protein level in the arterial wall, resulting in an increased responsiveness of isolated aortic rings to thrombin.

Conclusions— These data demonstrate that several progestins markedly potentiate the vascular procoagulant effects of thrombin by increasing the availability of membrane thrombin receptors in the smooth muscle, an effect that is most likely due to their glucocorticoid-like activity.


Key Words: thrombin • tissue factor • thrombosis • muscle, smooth • progestin




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Zerr-Fouineau, M. Jourdain, C. Boesch, M. Hecker, C. Bronner, and V. B. Schini-Kerth
Certain Progestins Prevent the Enhancing Effect of 17{beta}-Estradiol on NO-Mediated Inhibition of Platelet Aggregation by Endothelial Cells
Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 586 - 593.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. K. Dubey, E. K. Jackson, D. G. Gillespie, L. C. Zacharia, D. Wunder, B. Imthurn, and M. Rosselli
Medroxyprogesterone Abrogates the Inhibitory Effects of Estradiol on Vascular Smooth Muscle Cells by Preventing Estradiol Metabolism
Hypertension, April 1, 2008; 51(4): 1197 - 1202.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C.S. Vieira, R.A. Ferriani, A.A. Garcia, M.C. Pintao, G.D. Azevedo, M.K.O. Gomes, and M.F. Silva-de-Sa
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade
Hum. Reprod., August 1, 2007; 22(8): 2196 - 2201.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
B. Schutt, M. Kunz, and H. Blode
Coadministration of Estradiol/Drospirenone and Indomethacin Does Not Cause Hyperkalemia in Healthy Postmenopausal Women: A Randomized Open-Label Crossover Study
J. Clin. Pharmacol., June 1, 2007; 47(6): 774 - 781.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Hirano
The Roles of Proteinase-Activated Receptors in the Vascular Physiology and Pathophysiology
Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 27 - 36.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. Zerr-Fouineau, M. Chataigneau, C. Blot, and V. B. Schini-Kerth
Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors
FASEB J, January 1, 2007; 21(1): 265 - 273.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise
Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies
Endocr. Rev., October 1, 2006; 27(6): 575 - 605.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
C. P. Thomas, K. Z. Liu, and H. S. Vats
Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate {alpha}-ENaC and sgk1 expression in renal collecting duct epithelia
Am J Physiol Renal Physiol, February 1, 2006; 290(2): F306 - F312.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. K. Dubey, B. Imthurn, M. Barton, and E. K. Jackson
Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
Cardiovasc Res, May 1, 2005; 66(2): 295 - 306.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T. A. Luger, and M. D. Hollenberg
Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response
Endocr. Rev., February 1, 2005; 26(1): 1 - 43.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
Z. Salah, M. Maoz, I. Cohen, G. Pizov, D. Pode, M. S. Runge, and R. Bar-Shavit
Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression
FASEB J, January 1, 2005; 19(1): 62 - 72.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Edlund, E. Andersson, and G. Fried
Progesterone withdrawal causes endothelin release from cultured human uterine microvascular endothelial cells
Hum. Reprod., June 1, 2004; 19(6): 1272 - 1280.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Minami, A. Sugiyama, S.-Q. Wu, R. Abid, T. Kodama, and W. C. Aird
Thrombin and Phenotypic Modulation of the Endothelium
Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 41 - 53.
[Abstract] [Full Text] [PDF]